Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level

Human Gene Therapy

Volumn 11, Issue 1, 2000, Pages 113-125

  Mazzolini, Guillermo ^a   Qian, Cheng ^a   Narvaiza, Iñigo ^a   Barajas, Miguel ^a   Borrás Cuesta, Francisco ^a   Xie, Xiaoming ^a   Duarte, Marina ^a   Melero, Ignacio ^a   Prieto, Jesús ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; COMPLEMENTARY DNA; MITOMYCIN C; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 12;

ADENOVIRUS; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GENE TRANSFER; LIVER TUMOR; MOUSE; NONHUMAN; T LYMPHOCYTE;

ADENOVIRIDAE; ANIMALS; FEMALE; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOMAGNETIC SEPARATION; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0033971393     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050016201     Document Type: Article

References (43)

1. Addison, C.L., Bramson, J.L., Hitt, M.M., Muller, W.J., Gauldie, J., and Graham, F.L. (1998). Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther. 5, 1400-1409.
2. Boggio, K., Nicoletti, G., Di Carlo, E., Cavallo, F., Landuzzi, L., Melani, C., Giovarelli, M., Rossi, I., Nanni, P., De Giovanni, C., Bouchard, P., Wolf, S., Modesti, A., Musiani, P., Lollini, P.L., Colombo, M.P., and Forni, G. (1998). Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med. 188, 589-596.
3. Bramson, J.L., Hitt, M., Gauldie, J., and Graham F.L. (1997). Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther. 4, 1069-1076.
4. Brattain, M.G., Strobel Stevenson, J., Find, D., Webb, M., and Sarrif, A.M. (1980). Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res. 40, 2142-2146.
5. Caruso, M., Pham-Nguyen, K., Kwong, Y.-L., Xu, B., Kosai, K.-I., Finegold, M., Woo, S.L.C., and Chen, S.-H. (1996). Adenoviral-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc. Natl. Acad. Sci. U.S.A. 93, 11302-11306.
6. Chen, L. (1998). Immunological ignorance of silent antigens as an explanation of tumor evasion. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy. Immunol. Today 19, 27-30.
7. Chen, L., Linsley, P.S., and Hellström, K.E. (1993). Costimulation of T cells for tumor immunity. Immunol. Today 14, 483-485.
8. Corbett, T.H., Griswald, D.D., Roberts, B.J., Peckham, J.C., and Schabel, F.M. (1975). Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assay with a note on carcinogen structure. Cancer Res. 35, 2434-2439.
9. Coughlin, C.M., Salhany, K.E., Gee, M.S., Latemple, D.C., Kotenko, S., Ma, X., Gri, G., Wysocka, M., Kim, J.E., Liu, L., Liao, F., Farber, J.M., Pestka, S., Trinchieri, G., and Lee, W.M.F. (1998). Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9, 25-34.
10. α14 NKT cells in IL-12-mediated rejection of tumors. Science 278, 1623-1626.
11. Henslop, H.E., Ng, C.Y.C., Li, C., Smith, C.A., Loftin, S.K., Krance, R.A., Brenner, M.K., and Rooney, C.M. (1996). Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Med. 2, 551-555.
12. Hu, J., Kindsvogel, W., Busby, S., Bailey, C., Shi, Y., and Greenberg, P.D. (1993). An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J. Exp. Med. 177, 1681-1690.
13. Huang, A.Y.C., Gulden, P.H., Woods, A.S., Thomas, M.C., Tong, C.D., Wang, W., Engelhard, V.H., Pasternack, G., Cotter, R., Hunt, D., Pardoll, D.M., and Jaffee, E.M. (1996). The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. U.S.A. 93, 9730-9735.
14. Kast, W.M., Offringa, R., Peters, P.J., Voordouw, A.C., Meloen, R.H., Van Der Eb, A.J., and Melief, C.J.M. (1989). Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 59, 603-614.
15. Kos, F.J., and Engleman, E.G. (1996). Immune regulation: A critical link between NK cells and CTLs. Immunol. Today 17, 174-176.
16. Kurzawa Koblish, H., Hunter, C.A., Wysocka, M., Trinchieri, G., and Lee, W.M.F. (1998). Immune suppression by recombinant interleukin (rIL)-12 involves interferon γ induction of nitric oxide synthase 2 (iNOS) activity: Inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. J. Exp. Med. 188, 1603-1610.
17. Lanzavecchia, A. (1998). Licence to kill. Nature (London) 293, 413-414.
18. Lasarte, J.J., Corrales, F.J., Casares, N., Lopez-Diaz De Cerio, A., Qian, C., Xie, X., Borras-Cuesta, F., and Prieto, J. (1999). Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: The role of nitric oxide. J. Immunol. 162, 5270-5277.
19. Lynch, D.H., and Miller, R.E. (1991). Immunotherapeutic elimination of syngeneic tumors in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice. Eur. J. Immunol. 21, 1403-1410.
20. Martinotti, A., Stoppacciaro, A., Vagliani, M., Melani, C., Spreafico, F., Wysocka, M., Parmiani, G., Trinchieri, G., and Colombo, M.P. (1995) CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur. J. Immunol. 25, 137-146.
21. Mayordomo, J.I., Zorina, T., Storkus, W.J., Zitvogel, L., Celluzzi, C., Falo, L.D., Melief, C.J., Ildstad, S.T., Kast, W.M., Deleo, A.B., and Lotze, M.T. (1995). Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1, 1297-1302.
22. Mazzolini, G., Qian, C., Xie, X., Sun, Y., Lasarte, J.J., Drozdzik, M., and Prieto, J. (1999). Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing IL-12. Cancer Gene Ther. (in press).
23. Melero, I., Shufford, W.W., Ashe-Newby, S., Aruffo, A., Ledbetter, J.A., Hellström, K.E., Mittler, R.S., and Chen, L. (1997a). Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nature Med. 3, 682-685.
24. Melero, I., Singhal, M.C., McGowan, P., Haugen, H.S., Blake, J., Hellström, K.E., Yang, G., Clegg, C.H., and Chen, L. (1997b). Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J. Virol. 71, 3998-4004.
25. Ogawa, M., Tsutsui, T., Zou, J.-P., Mu, J., Wijesuriya, R., Yu, W.-G., Herrmann, S., Kubo, T., Fujiwara, H., and Hamaoka, T. (1997). Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12. Cancer Res. 57, 2216-2222.
26. Prieto, I., Hervás-Stubbs, S., Garcia-Granero, C., Berasaín, C., Riezu-Boj, J.I., Lasarte, J.J., Sarobe, P., Prieto, J., and Borrás-Cuesta, F. (1995). Simple strategy to induce antibodies of distinct specificity: Application to the mapping of gp120 and inhibition of HIV-1 infectivity. Eur. J. Immunol. 25, 877-883.
27. Qian, C., Bilbao, R., Bruña, O., and Prieto, J. (1995). Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology 22, 118-123.
28. Qian, C., Idoate, M., Bilbao, R., Sangro, B., Bruña, Vázquez, J., and Prieto, J. (1997). Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma. Hum. Gene Ther. 8, 349-358.
29. Riddell, S.R., and Greenberg, P.D. (1995). Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol. 13, 545-586.
30. Riddell, S.R., Greenberg, P.D., Overell, R.W., Loughran, T.P., Gilbert, M.J., Lupton, S.D., Agosti, J., Scheller, S., Coombs, R.W., and Corey, L. (1992). Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology. Hum. Gene Ther. 3, 319-338.
31. Ridge, J.P., Di Rosa, F., and Matzinger, P. (1998). A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (London) 393, 474-478.
32. Rossemberg, S.A., Yannelli, J.R., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Weber, J.S., Parkinson, D.R., Seipp, C.A., Einhorn, J.H., and White, D.E. (1994). Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86, 1159-1166.
33. Shurin, M.R., Esche, C., Péron, J.-M., and Lotze, M.T. (1997). Antitumor activities of IL-12 and mechanisms of action. Chem. Immunol. 68, 153-174.
34. Siders, W.M., Wright, P.W., Hixon, J.A., Alvord, W.G., Back, T.C., Wiltrout, R.H., and Fenton, R.G. (1998). T cell-and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus. J. Immunol. 160, 5465-5474.
35. Speiser, D.E., Miranda, R., Zakarian, A., Bachmann, M.F., McKall-Faienza, K., Odermatt, B., Hanahan, D., Zinkernagel, R.M., and Ohashi, P.S. (1997). Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implication for immunotherapy. J. Exp. Med. 186, 645-653.
36. Tannenbaum, C.S., Tubbs, R., Armstrong, D., Finke, J.H., Bukowski, R.M., and Hamilton, T.A. (1998). The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol. 161, 927-932.
37. Toda, M., Martuza, R.L., Kojima, H., and Rabkin, S.D. (1998). In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J. Immunol. 160, 4457-4464.
38. Topalian, S. (1994). MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr. Opin. Immunol. 6, 741-745.
39. Trinchieri, G. (1998). Interleukin-12: A cytokine at the interface of inflammation and immunity. Adv. Immunol. 70, 83-243.
40. Van Den Eynde, B., Lethé, B., Val Pel, A., De Plaen, E., and Boon, T. (1991). The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173, 1373-1384.
41. Wick, M., Dubey, P., Koeppen, H., Siegel, C.T., Fields, P.E., Chen, L., Bluestone, J.A., and Schreiber, H. (1997). Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186, 229-238.
42. Yee, C., Riddell, S.R., and Greenberg, P.D. (1997). Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 9, 702-708.
43. Zilocchi, C., Stoppacciaro, A., Chiodoni, C., Parenza, M., Terrazzini, N., and Colombo, M.P. (1998). Interferon γ-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 188, 133-143.